Interferon-α plus lamivudine vs lamivudine reduces breakthroughs, but does not affect sustained response in HBeAg negative chronic hepatitis B

Figure 1 Outline of the trial

Figure 2 Virological course. A: Treatment was administered up to 24 mo (vertical line). The trajectories of the mean log HBV DNA viral load are similar between the two groups. The following 6 mo were the follow-up period. B: Proportion of patients with viral load below detection (by ITT). DL: Detection limit; IFN: Interferon-α; mo: months; VL: HBV DNA viral load concentrations.

Figure 3 Combination treatment delayed the VBR compared to lamivudine monotherapy among patients who had lowered their HBV DNA concentrations below detection. IFN: Interferon-α.

Figure 4 Biochemical course. Mean transaminase levels per assessment time. Layout as per Figure 2. IFN: Interferon-α.

Figure 5 Combination therapy tended to delay BBR. IFN: Interferon-α.

Figure 6 Time to YMDD emergence. IFN: Interferon-α.